harrysnel schreef op 5 juli 2011 15:36:
Verder staat in dit PB:
"Conjugation technologies, such as conventional PEGylation, are unable to achieve this type of slowrelease mechanism, because the polymer cannot release the drug. Furthermore, with conventional PEGylation, the drug is trapped in the blood compartment and is unable to reach the surrounding tissues."
en.sanofi.com/binaries/20101221_ASCEN...Octoplus biedt al alternatief voor Peg-interferon en ik denk dat Zealand Pharma uit Denemarken mooi bij Octoplus aansluit. Zo proberen zij om behandeling diabetis van 2 maal daags naar 1 maal daags te brengen. Op website staat:
"Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs with favorable therapeutic attributes, and all drug candidates in its pipeline have been identified through the company’s own drug discovery activities. Zealand Pharma’s products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high."
en:
"Zealand Pharma also has a collaboration with Boehringer Ingelheim covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of diabetes and obesity..."
ZP2929 is nog pre-klinisch en 16 juni verscheen dit pb:
ir.zealandpharma.com/releasedetail.cf...Simon Sturge is momenteel werkzaam bij Boehringer Ingelheim en bekend met mogelijkheden die technologie van Octoplus biedt...
jmho